ClinicalTrials.gg
RecruitingNCT04344912CCU-COVID19Updated Oct 15, 2024

Impact of COVID19 Outbreak in Cardiac Acute Care

An observational study in Acute Coronary Syndrome, Heart Failure and COVID, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2020; still recruiting 6 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Acute Coronary Syndrome by Assistance Publique - Hôpitaux de Paris — 5 open to participants now, 5 under way, 1 of them phase 3. Acute Coronary Syndrome · Assistance Publique - Hôpitaux de Paris.

Started
2020
with 1 other
Observational
8 of 19
3 open now
Registered
12th of 19
by date

Among the 19 studies in Acute Coronary Syndrome by Assistance Publique - Hôpitaux de Paris, this one is one of 2 that started in 2020, is one of 8 observational ones, and was the 12th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

5 of the 19 studies in Acute Coronary Syndrome by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Acute Coronary Syndrome by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

This registry will evaluate the impact of the COVID19 outbreak on Cardiac patients admitted in the Intensive Care Unit of the Pitie-Salpetriere Hospital in Paris, France

Read the detailed description

Registry on Characteristics and outcomes of Cardiac patients (COVID- and COVID+) hospitalized in the Intensive Care Unit of the Pitie-Salpetriere Hospital in Paris, France

03

Conditions studied

  • Acute Coronary Syndrome
  • Heart Failure
  • COVID

Keywords

  • COVID19
  • Acute Coronary Syndrome
  • Myocardial Infarction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients treated in the CCU at Cardiology Institute of the Pitié-Salpêtrière Hospital, from Friday, March 20, 2020

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years and older
  • Admitted in the Cardiac Intensive Care Unit from March 20th 2020
  • Patient informed and having expressed his non-opposition to participate in the research

Exclusion criteria

Exclusion Criteria:

  • Minor patient
  • Patient who expressed opposition to participation in the study
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
500 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • COVID19- Population

    Patients without diagnosis of COVID19, as assessed by RT-PCR and CT scan

    Other: Data collection

  • COVID19+ Population

    Patients with a diagnosis of COVID19, as assessed by RT-PCR and CT scan

    Other: Data collection

Interventions

  • OtherData collection

    Diagnostic and prognostic evaluation of cardiac patients hospitalized in CCU during the COVID-19 outbreak; patient's immune status regarding the presence of SARS-CoV-2 specific antibodies

06

What researchers measure

Primary outcomes

  1. Incidence of recurrent Major Cardiovascular Events (MACE) and urgent rehospitalization

    Time frame: From admission to one year follow up

07

Study locations

1 of 1 sites recruiting
  • Unité de Soins Intensifs de Cardiologie, Pitié Salpêtrière Hospital, AP-HP
    Paris, 75013, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Open to collaboration

Time frame: The data will be available 12 months after the beginning of the Registry

Access criteria: to be determined

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Dec 2024, 57 months after the start.

Of 243 non-industry observational studies under Acute Coronary Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 57 months is above that.

Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2020
First posted
Apr 14, 2020
StartActual
Mar 20, 2020
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04344912
Collaborators
Action, France
Responsible party
Sponsor
First posted
Apr 14, 2020
Start date
Mar 20, 2020
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Oct 15, 2024

Study contacts

Johanne SILVAIN, MD PhD
Contact
johanne.silvain@aphp.fr
+33142162961
Johanne SILVAIN, MD PhD
study director · Sorbonne University, ACTION Group, AP-HP Pitié-Salpêtrière Hospital Paris France
Gilles MONTALESCOT, MD PhD
study chair · Sorbonne University, ACTION Group, AP-HP Pitié-Salpêtrière Hospital Paris France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion